The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 2, 2014, Pages 231-241

  Gujam, Fadia J A ^a   Going, James J ^a   Edwards, Joanne ^a   Mohammed, Zahra M A ^a   McMillan, Donald C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Breast cancer; Detection methods; Lymphatic and blood vessel invasion; Survival

Indexed keywords

EOSIN; HEMATOXYLIN;

BLOOD VESSEL INVASION; BREAST CANCER; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LYMPH VESSEL METASTASIS; PRIMARY TUMOR; REVIEW; SURVIVAL PREDICTION; SYSTEMATIC REVIEW; TUMOR INVASION; VASCULAR DISEASE;

BREAST CANCER; DETECTION METHODS; LYMPHATIC AND BLOOD VESSEL INVASION; SURVIVAL;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; PROGNOSIS;

EID: 84892539385     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.014     Document Type: Review

References (78)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer 2010, 46(March, 4):765-781.
2. Cancer Research UK Breast cancer statistics 2012, [accessed 16.10.12.]. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/.
3. Tumors of the mammary gland 1993, Armed Forces Institute of Pathology, Washington, DC. J. Rosai, L. Sobin (Eds.).
4. Teel P. Vascular invasion as a prognostic factor in breast carcinoma. Surgery, Gynecology & Obstetrics 1964, 118:1006-1008.
5. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., et al. Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Archives of Pathology & Laboratory Medicine 2000, 124(7):966-978.
6. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., Senn H., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology 2005, 16(10):1569-1583.
7. Saigo P.E., Rosen P.P. The application of immunohistochemical stains to identify endothelial-lined channels in mammary carcinoma. Cancer 1987, 59(1):51-54.
8. Bettelheim R., Mitchell D., Gusterson B.A. Immunocytochemistry in the identification of vascular invasion in breast-cancer. Journal of Clinical Pathology 1984, 37(4):364-366.
9. Van den Eynden G., Van der Auwera I., Van Laere S., Colpaert C., van Dam P., Dirix L., et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. British Journal of Cancer 2006, 94(11):1643-1649.
10. Hoda S.A., Hoda R.S., Merlin S., Shamonki J., Rivera M. Issues relating to lymphovascular invasion in breast carcinoma. Advances in Anatomic Pathology 2006, 13(6):308-315.
11. Freedman G.M., Li T., Polli L.V., Anderson P.R., Bleicher R.J., Sigurdson E., et al. Lymphatic space invasion is not an independent predictor of outcomes in early stage breast cancer treated by breast-conserving surgery and radiation. Breast Journal 2012, 18(5):415-419.
12. Lee A.K., Delellis R.A., Silverman M.L., Heatley G.J., Wolfe H.J. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. Journal of clinical oncology: Official Journal of the American Society of Clinical Oncology 1990, 8(9):1457-1465.
13. Pinder S.E., Ellis I.O., Galea M., Orourke S., Blamey R.W., Elston C.W. Pathological prognostic factors in breast-cancer .3. Vascular invasion - relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994, 24(1):41-47.
14. de Mascarel I., Bonichon F., Durand M., Mauriac L.H., Macgrogan G., Soubeyran I., et al. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. European Journal of Cancer 1998, 34(1):58-65.
15. van Tienhoven G., Voogd A.C., Peterse J.L., Nielsen M., Andersen K.W., Mignolet F., et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. European Journal of Cancer (Oxford, England: 1990) 1999, 35(1):32-38.
16. McCready D.R., Chapman J.A.W., Hanna W.M., Kahn H.J., Murray D., Fish E.B., et al. Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Annals of Surgical Oncology 2000, 7(6):416-426.
17. Jmor S., Al-Sayer H., Heys S.D., Payne S., Miller I., Ah-See A., et al. Breast cancer in women aged 35 and under: prognosis and survival. Journal of the Royal College of Surgeons of Edinburgh 2002, 47(5):693-699.
18. Woo C.S., Silberman H., Nakamura S.K., Ye W., Sposto R., Colburn W., et al. Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. American Journal of Surgery 2002, 184(4):337-340.
19. Kuru B., Camlibel M., Gulcelik M.A., Alagol H. Prognostic factors affecting survival and disease-free survival in lymph node-negative breast carcinomas. Journal of Surgical Oncology 2003, 83(3):167-172.
20. Neri A., Marrelli D., Roviello F., De Stefano A., Guarnieri A., Pallucca E., et al. Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer. Annals of Surgical Oncology 2005, 12(3):246-253.
21. Truong P.T., Yong C.M., Abnousi F., Lee J., Kader H.A., Hayashi A., et al. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy. Journal of the American College of Surgeons 2005, 200(6):912-921.
22. Trudeau M.E., Pritchard K.I., Chapman J.A.W., Hanna W.M., Kahn H.J., Murray D., et al. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Research and Treatment 2005, 89(1):35-45.
23. Lee A.H.S., Pinder S.E., Macmillan R.D., Mitchell M., Ellis I.O., Elston C.W., et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. European Journal of Cancer 2006, 42(3):357-362.
24. Beinart G., Gonzalez-Angulo A.M., Broglio K., Mejia J., Ruggeri A., Mininberg E., et al. Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival. Clinical Breast Cancer 2007, 7(11):867-874.
25. Grasic-Kuhar C., Bracko M., Zakotnik B. Risk factors for late relapse and death in patients with early breast cancer. Neoplasma 2008, 55(5):416-420.
26. Viale G., Rotmensz N., Maisonneuve P., Bottiglieri L., Montagna E., Luini A., et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Research and Treatment 2009, 116(2):317-328.
27. Ejlertsen B., Jensen M.B., Rank F., Rasmussen B.B., Christiansen P., Kroman N., et al. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. Journal of the National Cancer Institute 2009, 101(10):729-735.
28. Ragage F., Debled M., MacGrogan G., Brouste V., Desrousseaux M., Soubeyran I., et al. Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?. Cancer 2010, 116(13):3093-3101.
29. Viale G., Giobbie-Hurder A., Gusterson B.A., Maiorano E., Mastropasqua M.G., Sonzogni A., et al. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Annals of Oncology 2010, 21(2):245-254.
30. Thike A.A., Iqbal J., Cheok P.Y., Chong A.P.Y., Tse G.M-K., Tan B., et al. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. American Journal of Surgical Pathology 2010, 34(7):956-964.
31. Panet-Raymond V., Truong P.T., Alexander C., Lesperance M., McDonald R.E., Watson P.H. Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence. Cancer 2011, 117(10):2035-2043.
32. Sabatier R., Jacquemier J., Bertucci F., Esterni B., Finetti P., Azario F., et al. Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome. European Journal of Cancer (Oxford, England: 1990) 2011, 47(10):1537-1545.
33. Yi M., Mittendorf E.A., Cormier J.N., Buchholz T.A., Bilimoria K., Sahin A.A., et al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29(35):4654-4661.
34. Rakha E.A., Martin S., Lee A.H.S., Morgan D., Pharoah P.D.P., Hodi Z., et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 2012, 118(15):3670-3680.
35. Dinshaw K.A., Sarin R., Budrukkar A.N., Shrivastava S.K., Deshpande D.D., Chinoy R.F., et al. Safety and feasibility of breast conserving therapy in Indian women: two decades of experience at Tata Memorial Hospital. Journal of Surgical Oncology 2006, 94(2):105-113.
36. Bettelheim R., Penman H.G., Thorntonjones H., Neville A.M. Prognostic-significance of peritumoral vascular invasion in breast-cancer. British Journal of Cancer 1984, 50(6):771-777.
37. Magee B., Swindell R., Harris M., Banerjee S.S. Prognostic factors for breast recurrence after conservative breast surgery and radiotherapy: results from a randomised trial. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 1996, 39(3):223-227.
38. Shen J., Hunt K.K., Mirza N.Q., Buchholz T.A., Babiera G.V., Kuerer H.M., et al. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer 2005, 104(3):479-490.
39. Mohammed R.A., Martin S.G., Gill M.S., Green A.R., Paish E.C., Ellis I.O. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. American Journal of Surgical Pathology 2007, 31(12):1825-1833.
40. Kollias J., Murphy C.A., Elston C.W., Ellis I.O., Robertson J.F., Blamey R.W. The prognosis of small primary breast cancers. European Journal of Cancer (Oxford, England: 1990) 1999, 35(6):908-912.
41. Millis R.R., Springall R., Lee A.H.S., Ryder K., Rytina E.R.C., Fentiman I.S. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. British Journal of Cancer 2002, 86(3):396-401.
42. Ovcaricek T., Frkovic S.G., Matos E., Mozina B., Borstnar S. Triple negative breast cancer - prognostic factors and survival. Radiology and Oncology 2011, 45(1):46-52.
43. Kim S.H., Simkovich-Heerdt A., Tran K.N., Maclean B., Borgen P.I. Women 35 years of age or younger have higher locoregional relapse rates after undergoing breast conservation therapy. Journal of the American College of Surgeons 1998, 187(1):1-8.
44. Camp R.L., Rimm E.B., Rimm D.L. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer 2000, 88(1):108-113.
45. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer 1991, 68(6):1309-1317.
46. Clemente C.G., Boracchi P., Andreola S., Del Vecchio M., Veronesi P., Rilke F.O. Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 1992, 69(6):1396-1403.
47. Neville A.M., Bettelheim R., Gelber R.D., Save-Soderbergh J., Davis B.W., Reed R., et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1992, 10(5):696-705.
48. Gasparini G., Weidner N., Bevilacqua P., Maluta S., Dallapalma P., Caffo O., et al. Tumor microvessel density, P53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast-carcinoma. Journal of Clinical Oncology 1994, 12(3):454-466.
49. Genta F., Desanctis C., Ghiringhello B., Botta G., Sismondi P. Peritumoral blood and lymphatic vessel invasion as a prognostic indicator in stage-I breast-carcinoma. International Journal of oncology 1994, 4(1):163-167.
50. Dinshaw K.A., Budrukkar A.N., Chinoy R.F., Sarin R., Badwe R., Hawaldar R., et al. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy. International Journal of Radiation Oncology Biology Physics 2005, 63(4):1132-1141.
51. Yamauchi C., Hasebe T., Iwasaki M., Imoto S., Wada N., Fukayama M., et al. Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance. Human Pathology 2007, 38(2):247-259.
52. Schoppmann S.F., Bayer G., Aumayr K., Taucher S., Geleff S., Rudas M., et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Annals of Surgery 2004, 240(2):306-312.
53. Gudlaugsson E., Skaland I., Undersrud E., Janssen E.A.M., Soiland H., Baak J.P.A. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients. Modern Pathology 2011, 24(4):502-511.
54. Kurebayashi J., Kanomata N., Shimo T., Yamashita T., Aogi K., Kishimura R., et al. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poorer outcome in breast cancer patients treated with endocrine therapy alone. Breast Cancer 2012 Jun 12.
55. Tezuka K., Onoda N., Takashima T., Takagaki K., Ishikawa T., Wakasa T., et al. Prognostic significance of lymphovascular invasion diagnosed by lymphatic endothelium immunostaining in breast cancer patients. Oncology Reports 2007, 17(5):997-1003.
56. Lauria R., Perrone F., Carlomagno C., Delaurentiis M., Morabito A., Gallo C., et al. The prognostic value of lymphatic and blood-vessel invasion in operable breast-cancer. Cancer 1995, 76(10):1772-1778.
57. Mohammed R.A.A., Martin S.G., Mahmmod A.M., Macmillan R.D., Green A.R., Paish E.C., et al. Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. Journal of Pathology 2011, 223(3):358-365.
58. Matsunuma R., Oguchi M., Fujikane T., Matsuura M., Sakai T., Kimura K., et al. Influence of lymphatic invasion on locoregional recurrence following mastectomy: indication for postmastectomy radiotherapy for breast cancer patients with one to three positive nodes. International Journal of Radiation Oncology Biology Physics 2012, 83(3):845-852.
59. Nixon A.J., Neuberg D., Hayes D.F., Gelman R., Connolly J.L., Schnitt S., et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1994, 12(5):888-894.
60. Fisher E.R., Anderson S., Tan-Chiu E., Fisher B., Eaton L., Wolmark N. Fifteen-year prognostic discriminants for invasive breast carcinoma - National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 2001, 91(8):1679-1687.
61. Kato T., Kameoka S., Kimura T., Nishikawa T., Kobayashi M. The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. British Journal of Cancer 2003, 88(12):1900-1908.
62. Arnaout-Alkarain A., Kahn H.J., Narod S.A., Sun P.A., Marks A.N. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Modern Pathology 2007, 20(2):183-191.
63. D'Eredita G., Giardina C., Martellotta M., Natale T., Ferrarese F. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. European Journal of Cancer 2001, 37(5):591-596.
64. Rosen P.P., Groshen S., Kinne D.W. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1991, 9(9):1650-1661.
65. Saimura M., Fukutomi T., Tsuda H., Sato H., Miyamoto K., Akashi-Tanaka S., et al. Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor. Journal of Surgical Oncology 1999, 71(2):101-105.
66. Sampat M.B., Sirsat M.V., Gangadharan P. Prognostic significance of blood vessel invasion in carcinoma of the breast in women. Journal of Surgical Oncology 1977, 9(6):623-632.
67. Friedell G.H., Betts A., Sommers S.C. The prognostic value of blood vessel invasion and lymphocytic infiltrates in breast carcinoma. Cancer 1965, 18:164-166.
68. Ruiz U., Babeu S., Schwartz M.S., Soto E., McAuley R.A., Friedell G.H. Blood vessel invasion and lymph node metastasis: two factors affecting survival in breast cancer. Surgery 1973, 73(2):185-190.
69. Kister S.J., Sommers S.C., Haagensen C.D., Cooley E. Re-evaluation of blood-vessel invasion as a prognostic factor in carcinoma of the breast. Cancer 1966, 19(9):1213-1216.
70. TNM atlas illustrated guide to the TNM classification of malignant tumours 2005, Wiley, New York. C. Wittekind, L.H. Sobin, F.L. Greene (Eds.).
71. Gilchrist K.W., Gould V.E., Hirschl S., Imbriglia J.E., Patchefsky A.S., Penner D.W., et al. Interobserver variation in the identification of breast-carcinoma in intra-mammary lymphatics. Human Pathology 1982, 13(2):170-172.
72. Schoppmann S.F., Birner P., Studer P., Breiteneder-Geleff S. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Research 2001, 21(4A):2351-2355.
73. Mohammed R.A.A., Ellis I.O., Lee A.H.S., Martin S.G. Vascular invasion in breast cancer; an overview of recent prognostic developments and molecular pathophysiological mechanisms. Histopathology 2009, 55(1):1-9.
74. Rosen P.P., Saigo P.E., Braun D.W.J., Weathers E., DePalo A. Predictors of recurrence in stage I (T1N0M0) breast carcinoma. Annals of Surgery 1981, 193(1):15-25.
75. Chadha M., Chabon A.B., Friedmann P., Vikram B. Predictors of axillary lymph-node metastases in patients with T1 breast-cancer - a multivariate-analysis. Cancer 1994, 73(2):350-353.
76. Leitner S.P., Swern A.S., Weinberger D., Duncan L.J., Hutter R.V.P. Predictors of recurrence for patients with small (one centimeter or less) localized breast-cancer (T1A, B No Mo). Cancer 1995, 76(11):2266-2274.
77. Rosen P.P., Saigo P.E., Braun D.W., Weathers E., Depalo A. predictors of recurrence in stage I (T1N0M0) breast-carcinoma. Annals of Surgery 1981, 193(1):15-25.
78. Weigand R.A., Isenberg W.M., Russo J., Brennan M.J., Rich M.A. Blood-vessel invasion and axillary lymph-node involvement as prognostic indicators for human-breast cancer. Cancer 1982, 50(5):962-969.